|
122 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
12 Trials |
|
2436 News |
|
| «12...7891011121314151617...4950» |
- Imbruvica (ibrutinib) / AbbVie, J&J
Trial termination, Trial primary completion date: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Aug 13, 2015
P1, N=72, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Jul 2015; Inadequate accrual rate
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial suspension, Trial primary completion date: IPERGAY: On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men (clinicaltrials.gov) - Aug 13, 2015
P3, N=1900, Suspended, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Jul 2015; Inadequate accrual rate Recruiting --> Suspended | Trial primary completion date: Dec 2016 --> Mar 2016
- Trial initiation date: Accuracy of Portable Colposcopy and HPV Genotypes Among HIV+ Women (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=500, Not yet recruiting, Sponsor: Duke University
Recruiting --> Suspended | Trial primary completion date: Dec 2016 --> Mar 2016 Initiation date: Feb 2015 --> Aug 2015
- Enrollment change, Trial initiation date, Trial primary completion date: Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment. (clinicaltrials.gov) - Aug 13, 2015
P2, N=215, Completed, Sponsor: National Institute of Mental Health (NIMH)
Initiation date: Feb 2015 --> Aug 2015 N=143 --> 215 | Initiation date: Jan 2000 --> Jan 1990 | Trial primary completion date: Aug 2013 --> Aug 1996
- Trial completion, Adherence: Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison (clinicaltrials.gov) - Aug 13, 2015
P2, N=162, Completed, Sponsor: University of California, San Francisco
N=143 --> 215 | Initiation date: Jan 2000 --> Jan 1990 | Trial primary completion date: Aug 2013 --> Aug 1996 Recruiting --> Completed
- Trial completion: Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=699, Completed, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment closed, Enrollment change, Trial primary completion date: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - Aug 11, 2015
P3, N=428, Active, not recruiting, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting | N=538 --> 428 | Trial primary completion date: Apr 2016 --> Apr 2015
- ||| Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial completion, Trial primary completion date: Hepatic Safety of Eviplera (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=519, Completed, Sponsor: Fundaci
Not yet recruiting --> Active, not recruiting | N=538 --> 428 | Trial primary completion date: Apr 2016 --> Apr 2015 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jul 2015
- Enrollment closed, Trial primary completion date: BRM4: The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV (clinicaltrials.gov) - Aug 5, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: University of Miami
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Jan 2016
- | GSK2838232 / GSK
Trial completion, Enrollment change: A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (clinicaltrials.gov) - Aug 3, 2015
P1, N=24, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Jan 2016 Suspended --> Completed | N=40 --> 24
- Enrollment closed, Adherence: Study of Cell Phone SMS to Improve Adherence to ART in HIV Positive Young Women (clinicaltrials.gov) - Aug 3, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: The University of Texas Health Science Center, Houston
Suspended --> Completed | N=40 --> 24 Recruiting --> Active, not recruiting
- Ogsiveo (nirogacestat) / SpringWorks Therap
Enrollment change, Trial withdrawal: Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma (clinicaltrials.gov) - Jul 26, 2015
P2, N=0, Withdrawn, Sponsor: AIDS Malignancy Clinical Trials Consortium
Recruiting --> Active, not recruiting N=20 --> 0 | Not yet recruiting --> Withdrawn
- Enrollment change: Accuracy of the Pima (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=0, Withdrawn, Sponsor: Biosite
N=20 --> 0 | Not yet recruiting --> Withdrawn N=240 --> 0
- atorvastatin / Generic mfg.
Trial primary completion date: Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) - Jul 17, 2015
P4, N=15, Active, not recruiting, Sponsor: University of Pennsylvania
N=240 --> 0 Trial primary completion date: Jun 2014 --> Dec 2015
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment change: Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Jul 15, 2015
P2, N=279, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jun 2014 --> Dec 2015 N=150 --> 279
- Trial completion, Enrollment change: Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART (clinicaltrials.gov) - Jul 15, 2015
P0, N=105, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
N=150 --> 279 Active, not recruiting --> Completed | N=140 --> 105
- | Enrollment closed, Trial primary completion date: Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort (clinicaltrials.gov) - Jul 9, 2015
P2/3, N=250, Active, not recruiting, Sponsor: Boston Medical Center
Active, not recruiting --> Completed | N=140 --> 105 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Mar 2017
- sodium phenylbutyrate / Generic mfg.
Enrollment closed: Immune Reconstitution in HIV Disease (IREHIV) (clinicaltrials.gov) - Jul 9, 2015
P2, N=198, Active, not recruiting, Sponsor: Karolinska Institutet
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Mar 2017 Recruiting --> Active, not recruiting
- | Victrelis (boceprevir) / Roche, Merck (MSD)
Trial completion: BOC-HIV: HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin (clinicaltrials.gov) - Jul 9, 2015
P3, N=128, Completed, Sponsor: Anna Cruceta
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- AGS-004 / CoImmune
Trial primary completion date: A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004 (clinicaltrials.gov) - Jul 8, 2015
P1/2, N=12, Recruiting, Sponsor: Cynthia L Gay, MD
Not yet recruiting --> Completed Trial primary completion date: Mar 2016 --> Dec 2016
- GSK2838232 / GSK
Enrollment change: A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (clinicaltrials.gov) - Jul 8, 2015
P1, N=20, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Mar 2016 --> Dec 2016 N=12 --> 20
- ||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment change, Trial primary completion date: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - Jul 8, 2015
P3, N=428, Active, not recruiting, Sponsor: ViiV Healthcare
N=12 --> 20 N=538 --> 428 | Trial primary completion date: Oct 2015 --> Apr 2015
- || Enrollment closed: Viral and Host Factors in the Transmission and Pathogenesis of HIV (clinicaltrials.gov) - Jul 3, 2015
P=N/A, N=600, Active, not recruiting, Sponsor: Rockefeller University
N=538 --> 428 | Trial primary completion date: Oct 2015 --> Apr 2015 Recruiting --> Active, not recruiting
- | HSV vaccine (GEN-003) / Genocea, Shionogi
Enrollment closed, Trial primary completion date: Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study (clinicaltrials.gov) - Jul 2, 2015
P2, N=45, Active, not recruiting, Sponsor: Genocea Biosciences, Inc.
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jun 2015 --> May 2016
- Trial completion: X LIBRIS: X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study (clinicaltrials.gov) - Jul 1, 2015
P=N/A, N=90, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jun 2015 --> May 2016 Recruiting --> Completed
- Enrollment open: Healthy Options: Group Psychotherapy for HIV-positive Depressed Perinatal Women. (clinicaltrials.gov) - Jun 29, 2015
P=N/A, N=720, Enrolling by invitation, Sponsor: Harvard Medical School
Recruiting --> Completed Active, not recruiting --> Enrolling by invitation
- GSK2838232 / GSK
Enrollment change, Trial termination: A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (clinicaltrials.gov) - Jun 29, 2015
P1, N=12, Terminated, Sponsor: GlaxoSmithKline
Active, not recruiting --> Enrolling by invitation N=20 --> 12 | Suspended --> Terminated; Study prematurely terminated due to safety concerns leading to clinical hold
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial primary completion date: Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy (clinicaltrials.gov) - Jun 25, 2015
P1/2, N=65, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=20 --> 12 | Suspended --> Terminated; Study prematurely terminated due to safety concerns leading to clinical hold Trial primary completion date: Jan 2016 --> Aug 2017
- | Trial completion: PEARLS: Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings (clinicaltrials.gov) - Jun 24, 2015
P4, N=1571, Completed, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Jan 2016 --> Aug 2017 Active, not recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: Pilot Assessment of Lopinavir/Ritonavir and Maraviroc (clinicaltrials.gov) - Jun 23, 2015
P4, N=3, Terminated, Sponsor: Rodwick, Barry M., M.D.
Active, not recruiting --> Completed N=25 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jul 2011 --> May 2015; unable to enroll expected number of subjects
- Trial completion, Enrollment change, Trial primary completion date: IYG-AI/AN: Internet-Based Sexual Health Education for Middle School Native American Youth (clinicaltrials.gov) - Jun 23, 2015
P=N/A, N=574, Completed, Sponsor: The University of Texas Health Science Center, Houston
N=25 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jul 2011 --> May 2015; unable to enroll expected number of subjects Recruiting --> Completed | N=1200 --> 574 | Trial primary completion date: Jun 2014 --> Jan 2015
- || Vocabria (cabotegravir oral) / ViiV Healthcare
Trial completion: Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir (clinicaltrials.gov) - Jun 22, 2015
P3, N=37, Completed, Sponsor: ViiV Healthcare
Recruiting --> Completed | N=1200 --> 574 | Trial primary completion date: Jun 2014 --> Jan 2015 Active, not recruiting --> Completed
- rosuvastatin / Generic mfg.
Enrollment open: The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients (clinicaltrials.gov) - Jun 18, 2015
P4, N=82, Recruiting, Sponsor: Ottawa Heart Institute Research Corporation
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents (clinicaltrials.gov) - Jun 16, 2015
P2/3, N=50, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Oct 2015
- ||||||| darunavir/ritonavir / Generic mfg.
Trial completion, Combination therapy, Monotherapy: A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (clinicaltrials.gov) - Jun 15, 2015
P3, N=274, Completed, Sponsor: Janssen-Cilag International NV
Trial primary completion date: Jun 2015 --> Oct 2015 Active, not recruiting --> Completed
- ||| Isentress (raltegravir) / Merck (MSD)
Enrollment change: TROP: Switch From Tenofovir to Raltegravir for Low Bone Mineral Density (clinicaltrials.gov) - Jun 12, 2015
P4, N=52, Completed, Sponsor: St Vincent's Hospital, Sydney
Active, not recruiting --> Completed N=37 --> 52
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial primary completion date: Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents (clinicaltrials.gov) - Jun 11, 2015
P2, N=150, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=37 --> 52 Trial primary completion date: May 2016 --> Aug 2017
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: QuaDar: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (clinicaltrials.gov) - Jun 11, 2015
P4, N=10, Recruiting, Sponsor: University of British Columbia
Trial primary completion date: May 2016 --> Aug 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial primary completion date: PREP-5: PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5 (clinicaltrials.gov) - Jun 11, 2015
P4, N=50, Recruiting, Sponsor: St. Michael's Hospital, Toronto
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Isentress (raltegravir) / Merck (MSD)
Trial primary completion date: Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir (clinicaltrials.gov) - Jun 11, 2015
P2, N=25, Recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Oct 2015 --> Feb 2016
- THV-01 / TheraVectys
Trial primary completion date: Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART). (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=38, Active, not recruiting, Sponsor: Theravectys S.A.
Trial primary completion date: Oct 2015 --> Feb 2016 Trial primary completion date: Nov 2014 --> Nov 2015
- Trial primary completion date: Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: George Washington University
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Jun 2014 --> Jun 2016
- Trial primary completion date: The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=30, Recruiting, Sponsor: George Washington University
Trial primary completion date: Jun 2014 --> Jun 2016 Trial primary completion date: Jul 2014 --> Sep 2015
- Trogarzo (ibalizumab IV) / Theratechnologies, TaiMed Biologics
Trial primary completion date: Investigator-Sponsored Protocol - Continued Use of Ibalizumab (clinicaltrials.gov) - Jun 11, 2015
P2, N=4, Active, not recruiting, Sponsor: Kaiser Permanente
Trial primary completion date: Jul 2014 --> Sep 2015 Trial primary completion date: May 2015 --> May 2017
- || Trial primary completion date: Neurobehavioral Model of HIV in Injection Drug Users (clinicaltrials.gov) - Jun 11, 2015
P1, N=836, Active, not recruiting, Sponsor: The City College of New York
Trial primary completion date: May 2015 --> May 2017 Trial primary completion date: Mar 2014 --> Mar 2015
- || lopinavir/ritonavir / Generic mfg.
Trial initiation date, Trial primary completion date: Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=3200, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Mar 2014 --> Mar 2015 Initiation date: Jan 2005 --> Aug 2006 | Trial primary completion date: Jan 2018 --> Jan 2016
- ||| Trial completion, Trial primary completion date: imPACT: Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=381, Completed, Sponsor: University of North Carolina, Chapel Hill
Initiation date: Jan 2005 --> Aug 2006 | Trial primary completion date: Jan 2018 --> Jan 2016 Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> May 2015
- Trial completion, Enrollment change: Leukapheresis for Research on HCV-Coinfected Patients (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=327, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> May 2015 Recruiting --> Completed | N=700 --> 327
- Enrollment closed: Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients (clinicaltrials.gov) - Jun 10, 2015
P=N/A, N=600, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Completed | N=700 --> 327 Recruiting --> Active, not recruiting
- Trial completion: BIDMED: Brief Intervention for Drug Misuse in the Emergency Department (clinicaltrials.gov) - Jun 10, 2015
P2, N=1030, Completed, Sponsor: Rhode Island Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed